|Cat. No. HS-454 017||200 µl purified IgG, lyophilized. Albumin and azide were added for stabilization. For reconstitution add 200 µl H2O. Then aliquot and store at -20°C to -80°C until use.|
WB: 1 : 1000 gallery
ICC: 1 : 100 gallery
IHC-P/FFPE: 1 : 100 gallery
|Subtype||IgG2a (κ light chain)|
|Immunogen||Synthetic peptide corresponding to AA 446 to 460 from human CK7 (UniProt Id: P08729)|
Epitop: AA 446 to 460 from human CK7 (UniProt Id: P08729)
Reacts with: human (P08729).
No signal: mouse (Q9DCV7).
Other species not tested yet.
|Specificity||Specific for Cytokeratin 7|
Cytokeratin 7 staining in a human CK7-positive pancreatic adenocarcinoma (A) and a human CK7-negative colon carcinoma xenograft (B)
Cytokeratins are cytoskeleton proteins of epithelial tissues, contributing to the mechanical stabilization of the cells. The cytokeratin family consists of at least 20 isotypes, which are largely specific for particular organs or tissue types. Therefore, immunohistochemical staining of cytokeratins is clinically used for diagnosis of carcinomas, in particular of unclear metastases and in precise classification and subtyping of tumors (1). Cytokeratin 7 (CK7) is expressed in healthy bladder, in the female genital tract epithelium, in mesothelium and in the lung (2). In tumors, CK7 expression is found in the majority of carcinoma types, with the exception of those carcinomas arising from the colon, prostate, kidney and thymus (3). Furthermore, CK7 expression can have prognostic relevance, e.g. adverse prognostic factor in lung cancer (4), or predictive relevance, e.g. predictive factor of response to concurrent radiochemotherapy in advanced cervical cancer (5).